Type I interferons (a/b) have significant antitumor activity although their short half-life and systemic side effects have limited their clinical utility. An alternative dosing schedule of continuous, low-level delivery, as is achieved by gene therapy, rather than intermittent, high concentration pulsed-dosing, might avoid the toxicity of interferon while maintaining its antitumor efficacy. We have tested a gene therapy approach in murine tumor models to treat malignancies that have shown responsiveness to interferon in clinical trials. The tumor cell lines used were moderately sensitive to the direct effects of human interferon-b (hIFN-b) in vitro. For in vivo testing, systemic delivery of hIFN-b was generated following liver-targeted delivery of adeno-associated virus (AAV) vector carrying the hIFN-b transgene. This prevented engraftment of subcutaneous human gliomas, and orthotopic, localized (intrarenal) and disseminated (primarily pulmonary) human renal cell carcinomas; and caused regression of established tumors at these sites. In a syngeneic, immunocompetent model of melanoma, AAV IFN-b treatment limited subcutaneous tumor growth and prevented disseminated disease. A significant decrease in mean intratumoral vessel density was demonstrated in hIFN-b-treated tumors, suggesting that in addition to a direct tumoricidal effect, the antitumor efficacy of AAV IFN-b in this study was due to its ability to inhibit angiogenesis.
Introduction
Since their identification in the late 1950s as potent antiviral agents, 1 type I interferons (a/b) have become recognized for their antitumor efficacy against both solid and hematologic malignancies. [2] [3] [4] Their pleiotropic antitumor mechanisms of action include direct tumor cell cytotoxicity 5 and indirect activity through immunomodulation 6 and inhibition of angiogenesis. [7] [8] [9] [10] [11] Despite exciting early preclinical results, the antitumor efficacy of type I interferons in clinical trials has been somewhat limited. 12 Significant contributing factors for this appear to include the very short half-life of type I interferons, making effective dosing problematic, and their toxicity at high doses. 13 An alternative dosing schedule in which there is continuous, low-level delivery of these agents might avoid the toxicity of interferon while maintaining antitumor efficacy. 8 This type of pharmacokinetics can, perhaps, best be achieved by a gene therapy-mediated approach to the delivery of these cytokines.
Gene therapy strategies for delivering antitumor drugs are already being tested in a number of different preclinical tumor models, with some success. However, most of these studies have used either retroviral vector producer cells, naked DNA, or adenoviral vectors. 14 Unfortunately, retroviral vector producers may be impractical for human use and the transfer of naked DNA is typically an inefficient, transient process; adenoviralmediated gene transfer is also complicated by transient transgene expression as well as a host immune response to transduced target cells. Adeno-associated virus (AAV) is a nonpathogenic, helper-dependent member of the parvovirus family. A number of properties make AAV-based vectors promising for antiangiogenic gene therapy. 15 Most importantly, unlike the other gene delivery systems just mentioned, recombinant AAV (rAAV) vectors have been shown to direct long-term transgene expression from nondividing cells 16, 17 despite the uncertainties regarding whether the genome remains episomal or integrates as high molecular weight concatamers. In addition, these vectors have an excellent safety profile. Also unlike other vectors of viral origin, AAV has never been associated with any human disease and is naturally replication deficient, thereby providing an added measure of safety. In addition, rAAV is nonimmunogenic; the genes encoding wild-type viral proteins have been removed, thus reducing the potential for invoking a cell-mediated immune response due to the expression of foreign viral proteins. For these reasons, we have chosen to use rAAV vectors to mediate delivery of the cDNA for human interferon-b (hIFN-b) to the liver to assess the efficacy of continuous, systemic delivery of interferon-b (IFN-b) in preclinical murine models of tumor types known to be sensitive to this agent.
Materials and methods

Cell lines
The human glioblastoma (U87) and renal cell carcinoma (786-O) cell lines, purchased from American Type Culture Collection (Manassas, VA) and the murine melanoma (B16F10) cell line, provided by Dr J Fidler (Houston, TX) were maintained in Dulbecco's modified Eagle's medium (DMEM) (Mediatech Cellgro, Herndon, VA) supplemented with 10% heat-inactivated fetal bovine serum (Mediatech), 100 units per ml penicillin and 100 mg per ml streptomycin (GIBCO BRL, Grand Island, NY), and 2 mM L-glutamine (GIBCO). 293T cells (human embryonic kidney cells expressing SV40 large T antigen) were also purchased from ATCC and maintained in the same medium.
Effects of IFN-b in vitro
Tumor cells were plated at a density of approximately 3 Â 10 5 cells per well. The following day 10 000 IU/ml of recombinant hIFN-b (Avonex s , Biogen Inc., Cambridge, MA) was added to the culture medium. The culture medium was aspirated and the cells were refed with hIFNb containing medium each day. Cell counts, Annexin V FACS and cell cycle analysis were performed on the tumor cells after 96 h of culture with recombinant hIFN-b. All experiments were performed in duplicate.
rAAV vector construction, production, and purification Construction of the pAV2 CAG hIFN-b and pAV2 CAG hFIX vector plasmids has been described previously. 18 The hIFN-b cDNA was purchased from InvivoGen (San Diego, CA). These plasmids include the CMV-IE enhancer, b-actin promoter, a chicken b-actin/rabbit b globin composite intron, and a rabbit b globin polyadenylation signal (CAG) mediating the expression of the cDNA for human IFN-b or human clotting factor IX. The expression cassettes are flanked by the AAV-2 inverted terminal repeats (ITR) (Figure 1 20 without the adenoviral ITRs, and with better plasmid yields in Escherichia coli (JTG, unpublished data). These rAAV-2/8 vectors were purified using our recently described ion exchange chromatography method. 21 Standard slot-blot analysis was used to determine the vector particle titer. The vector stocks were consistently free of contamination with wt AAV and cellular and adenoviral proteins as judged by our previously described methods. 22 Murine tumor models Subcutaneous (heterotopic) human glioblastoma xenografts were established in male B6.CB17-Prkdco SCID4SzJ mice (Jackson Laboratory, Bar Harbor, ME) by right flank injection of 2.0 Â 10 6 U87 cells in 200 ml PBS. Using a similar approach, subcutaneous murine melanomas were established in syngeneic male C57Bl/6J mice (Jackson Laboratory, Bar Harbor ME). Intrarenal (orthotopic) renal cell carcinoma xenografts were established in male C.B-17 SCID mice (Jackson Laboratory) by injection of 1.5 Â 10 6 786-O cells in 150 ml PBS under the capsule of the left kidney via a left subcostal incision during administration of 2% isoflourane. Pulmonary metastases were established by injecting 2.0 Â 10 6 786-O or B16F10 cells via tail vein. AAV vector particles were also administered via tail vein, in a volume of 250 ml. Measurements of the subcutaneous tumors were performed in two dimensions with calipers and volumes calculated as width 2 Â length Â 0.5. Mice with retroperitoneal tumors were followed by ultrasonography. At the time of killing, tumors were excised and portions of the tumors were snap-frozen in liquid nitrogen or fixed in formalin. All murine experiments were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of St Jude Children's Research Hospital.
hIFN-b immunoassay
Quantitation of AAV-mediated human IFN-b expression in mouse sera was performed by a commercially available sandwich immunoassay (ELISA, PBL Biomedical). The sensitivity range for this assay is 250-10 000 pg/ml.
Tumor immunohistochemistry
Formalin-fixed, paraffin-embedded 5 mm tumor specimens were analyzed by immunohistochemistry with an anti-CD34 antibody to determine endothelial cell density as previously described. 23 Briefly, tissue sections were deparaffinized in xylene. Heat-induced epitope retrieval in citrate buffer (Zymed, South San Francisco, CA) was performed at 4951C for 15 min. Endogenous peroxidase activity was blocked by incubation with 3% H 2 O 2 (Humco, Texarcana, TX) and the slides were then incubated with rat anti-mouse CD34 antibody (RAM34, PharMingen, San Diego, CA) for 10 min followed by a biotinylated secondary rabbit anti-rat antibody. Following incubation with streptavidin conjugated to horseradish peroxidase (DAKO), a substrate containing the chromagen DAB (3, 3 0 diaminobenzidine tetrahydrochloride) was added. Control concentration matched, species appropriate immunoglobulins (DAKO) were also used. Slides were counter-stained with hematoxylin. Endothelial cell density in hot spots was determined with light microscopy at Â 400 by the method described previously by Weidner et al. 24 
Statistical analyses
Results are reported as means7s.e. The sigmaplot program (SPSS, Inc., Chicago, IL) was used to analyze and graphically present the data. An unpaired Student's t-test was used to analyze statistical differences between in vitro cell densities, apoptosis, and cell cycle differences as well as xenograft volume, tumor angiogenic protein expression, and intratumoral microvessel density. A Pvalue less than 0.05 was considered to be statistically significant. 
Results
Tumor cell sensitivity to IFN-b in vitro
Prevention of tumor engraftment by AAV-mediated IFN-b delivery
In the first set of in vivo studies, the ability of continuously delivered hIFN-b to prevent human tumor cell engraftment in immunodeficient mice was evaluated. The results are summarized in Table 1 . At 3 weeks following tail vein administration of 6 Â 10 10 vector particles of rAAV2/8 CAG hIFN-b to male B6.CB17-PrkdcoSCID4SzJ mice, stable systemic hIFN-b levels of 1.8070.19 ng/ml were confirmed. U87 cells were then injected subcutaneously. Tumor engraftment was prevented in each of five mice, all of whom were alive with stable expression of hIFN-b, without evidence of disease, 10 months after tumor cell injection. Mice (n ¼ 5) that had received a similar dose of the control vector, rAAV2/8 CAG hFIX, were killed 4 weeks after tumor cell injection, with each having a tumor greater than 2 cm in longest dimension.
Since AAV hIFN-b was so effective at preventing engraftment of U87 cells in these initial experiments, we sought to determine whether there was a dose-response effect of the AAV hIFN-b by administering a series of sequentially lower doses of vector to mice prior to tumor challenge. Cohorts of five male B6.CB17-Prkdco SCID4SzJ mice received 1 Â 10 9 , 5 Â 10
9
, and 1 Â 10 10 vp. After 3 weeks, hIFN-b expression in these mice was 2647142, 4187193, and 6377222 pg/ml, respectively. However, despite using doses 60-fold lower than had originally been used, no tumors grew in any of the mice treated with AAV hIFN-b, including those that had received the lowest dose of vector and in whom systemic hIFN-b was just above the lower limits of detection by ELISA.
A similar ability to prevent tumor cell engraftment was observed when using a different tumor cell line in orthotopic sites of disease. At 2 weeks following tail vein administration of vector (6 Â 10 10 vp/mouse), 786-O renal cell carcinoma cells (1 Â 10 6 cells) were injected either into the renal capsule, in an attempt to generate orthotopic, localized disease, or via tail vein, to generate disseminated disease, primarily in the lungs of male C.B-17 SCID mice. Mice that received AAV hIFN-b had a mean level of hIFN-b expression of 4327159 pg/ml at the time of tumor challenge. No histologic evidence of disease was found in the kidney of the five mice that had received intrarenal injection of tumor cells when these mice were killed 6 weeks following tumor cell implantation. Mice that received control vector each had grossly visible tumors at this time, with a mean tumor weight ¼ 0.9270.13 g. In the model of disseminated, pulmonary disease, the five mice that had received AAV hIFN-b and then tumor cells via tail vein were all alive 7 months following tumor cell injection. Two of these mice were recently killed and no gross or histologic evidence of pulmonary disease was detected (data not shown). The five mice that had received control vector all developed respiratory distress and were killed 9 weeks following tumor cell injection. Each had extensive, gross, bilateral pulmonary disease.
Finally, we sought to test the efficacy of AAV hIFN-b at preventing engraftment of syngeneic murine melanoma cells in immocompetent mice, again using models of localized and disseminated disease. Although localized, subcutaneous engraftment was not completely prevented in mice that had been given AAV hIFN-b prior to tumor cell challenge, the mean tumor size, 3 weeks following tumor cell injection, was significantly lower in the five mice expressing hIFN-b (at an average level of 18327104 pg/ml), than those that had received control vector (2.4370.51 vs 4.7770.37 g, Po0.01). Immunohistochemical analysis of the AAV-hIFN-b-treated tumors with an anti-CD34 antibody revealed that there was a significantly lower endothelial cell density in these tumors as compared with control (5.2 counts/field vs 10.1 counts/ field, Po0.002) (Figure 3) . ELISA of tumor protein lystates did not demonstrate a significant difference in VEGF or bFGF expression in hIFN-b-treated tumors as compared to control tumors, however (data not shown).
AAV hIFN-b did prevent the establishment of disseminated murine melanoma, however. When mice were killed 6 weeks following tail vein administration of 2 Â 10 5 B16F10 cells, no gross or histologic evidence of melanoma could be detected (Figure 4 ) in the lungs of any of the five mice given AAV hIFN-b (mean hIFN-b level ¼ 1610774 pg/ml) while control treated mice had gross, miliary disease in the lungs.
In separate cohorts of mice, the impact on survival was assessed. All five mice that had received control vector prior to tumor cell challenge were dead within 4 weeks of 
Discussion
In this series of experiments, we have demonstrated significant antitumor efficacy for AAV-mediated delivery of hIFN-b in different murine models of malignancy. Three tumor types were chosen for study: glioma, renal cell carcinoma, and melanoma, as these histologies have shown sensitivity to type I interferons in clinical trials. [25] [26] [27] However, the success of interferon has been limited by significant toxicity. An alternative dosing schedule in which there is continuous, low-level delivery, as is achieved by gene therapy, might avoid the toxicity of interferon while maintaining its antitumor efficacy.
Others have used a gene therapy-mediated approach to the delivery of type I interferons as part of an anticancer strategy, with some success. [28] [29] [30] [31] However, this is the first study in which continuous, long-term delivery of hIFN-b was achieved through a liver-targeted, AAV-mediated gene therapy approach.
This strategy of liver-targeted AAV-mediated delivery of hIFN-b proved to be highly efficacious. Engraftment of human gliomas and renal cell carcinomas in immunodeficient mice that had received AAV hIFN-b prior to tumor cell challenge was completely prevented in both localized and disseminated tumor models. In addition, it was subsequently shown that this approach could even effect complete regression of small established glioma and renal cell carcinoma xenografts with no evidence of residual disease being detected on microscopic analysis.
Type I interferons are known to have pleiotrophic antitumor actions that include direct inhibition of tumor cell proliferation through both cell cycle arrest and induction of apoptosis 5 and indirect antitumor activity through inhibition of angiogenesis [7] [8] [9] [10] [11] and immunomodulation. 6 The relative importance of each of these antitumor mechanisms of action in these experiments is uncertain. The in vitro analyses suggest that both the U87 glioma cells and the 786-O renal cell carcinoma cells, and to a lesser extent, the B16F10 murine melanoma cells are susceptible to the direct cytotoxic effects of hIFN-b. As the gliomas and renal cell carcinomas were established in immunodeficient mice it is unlikely that an immunodulatory effect of hIFN-b had a significant role in its antitumor activity although these particular strains of mice do retain some minimal natural killer cell activity.
In addition, however, immunohistochemical analysis of the treated subcutaneous melanoma cells demonstrated a significant decrease in the mean intratumoral vessel density of treated tumors, suggesting that inhibition of angiogenesis was a contributing factor to the antitumor efficacy of hIFN-b. This antiangiogenic effect did not appear to be mediated through the direct downregulation of expression of the two major angiogenic factors, VEGF and bFGF, however, suggesting that this effect may reflect a direct toxicity to the endothelial cells. The studies with the murine melanoma cells were performed in immunocompetent mice with an intact immune system. However, published data suggest that there is little crossspecies reactivity for human and mouse interferon making it unlikely that the mouse immune system would be affected by human IFN-b. 32 In fact, it is somewhat surprising to see the degree of antitumor efficacy that hIFN-b had against a mouse tumor cell line grown in mice. Perhaps at higher levels of hIFN-b, there is some degree of cross-species reactivity. This may be why host angiogenesis was affected in this syngeneic mouse tumor model. In addition, therefore, there may have been some cross-species antitumor immunomodulatory effect of human IFN-b. The greater efficacy against disseminated melanoma as compared to localized disease may reflect the concentration of tumor cells at any particular site or focus of disease.
As a result of the general lack of cross-species reactivity, we have recently cloned the cDNA for murine IFN-b into our AAV vector plasmid and are preparing to test it in our transplant tumor models as well as transgenic tumor models. As a result of its presumed ability to stimulate the host immune system and, potentially, to effect greater direct tumor cell toxicity to a murine tumor cell line, we would anticipate improved efficacy against the melanoma cell line. This will also afford us a better opportunity to assess the potential toxicities of IFN-b in our mouse model. Thus, in this study, continuous delivery of hIFN-b was highly effective at preventing tumor engraftment and regression of small, established tumors in localized and disseminated models of glioma, renal cell carcinoma and melanoma. In addition to a direct cytotoxic effect, the antitumor efficacy of hIFN-b appeared to be mediated, at least in part, by its ability to restrict angiogenesis. Gene therapy-mediated delivery of hIFN-b may ultimately prove to be the most efficacious delivery approach, establishing continuous levels of expression of this otherwise short-lived cytokine.
